Altimmune, Inc. (ALT) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds opening new positions versus the previous quarter. Insiders were net buyers over the last 90 days ($96.4K bought vs $0 sold). Latest close $1.39 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 18, 2026 · Congress to Nov 16, 2026.
Deep Track Capital · RA Capital Management · Viking Global Investors — 3 tracked funds hold ALT. See all holders.
Insiders bought on the open market (4 purchases, $96.4K) vs 0 sales ($0). Latest buy: Nov 18, 2026. Insider trading
Oruka Therapeutics, Inc. (ORKA) · Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Deep Track Capital | 0.85% | 19,250,000 | NEW Q3 filed Nov 16 |
| RA Capital Management | 0.17% | 6,500,000 | NEW Q3 filed Nov 16 |
| Viking Global Investors | 0.06% | 6,700,000 | NEW Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -51.4% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 211 of 8,857 filers |
| Long-only filers among them | 210 |
| Change vs 2026 Q1 | +44 net · 206 entered · 162 exited |
| Shares reported, all filers | 150,053,467 |
| Reported value, all filers | $464.3M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $41.0K |
| Net income · FY2025 | $-88.1M |
| Total assets · FY2025 | $279.9M |
| Shares outstanding | 194,517,701 |
| Market cap (at latest close) | $270.4M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 7, 2026.
| Shares short · Oct 15, 2026 | 42,233,791 |
| Share of shares outstanding | 21.71% |
| Days to cover | 10.42 |
Shares short at recent settlements — Jul 31, 2026: 51.9M · Aug 14, 2026: 51.0M · Aug 31, 2026: 49.7M · Sep 15, 2026: 51.7M · Sep 30, 2026: 46.1M · Oct 15, 2026: 42.2M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 7, 2026.
| Shares failed to deliver · Oct 14, 2026 | 631 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | <0.1% |
Fails to deliver at recent settlements — Jul 31, 2026: 3K · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 631.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 7, 2026.
4 insiders bought on the open market in the last 90 days (4 purchases, $96.4K), against 0 sales by 0 insiders ($0). Latest buy: Nov 18, 2026.
CEO/CFO boughtSource: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 18, 2026 | MENZIUSO RICHARD THOMAS | Principal Accounting Officer | Buy | 10,000 | $1.42 | $14.2K | SEC filing |
| Nov 13, 2026 | Pisano Wayne | Buy | 10,000 | $1.64 | $16.4K | SEC filing | |
| Nov 13, 2026 | Durso Jerome Benedict | President and CEO | Buy | 30,700 | $1.62 | $49.7K | SEC filing |
| Nov 13, 2026 | WEAVER GREGORY L | Chief Financial Officer | Buy | 10,000 | $1.62 | $16.2K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 15, 2026 | TANG CAPITAL MANAGEMENT, LLC | SC 13G/A | 666,022 | 0.3% | Mar 31, 2026 | SEC filing |
| May 12, 2026 | STATE STREET CORPORATION | SC 13G | 7,145,550 | 5.5% | Mar 31, 2026 | SEC filing |
| May 1, 2026 | RA Capital Management, L.P. | SC 13G | 13,000,000 | 6.5% | Apr 24, 2026 | SEC filing |
| May 1, 2026 | TCG Crossover GP II, LLC | SC 13G | 10,000,000 | 5.0% | Apr 24, 2026 | SEC filing |
| May 1, 2026 | VIKING GLOBAL INVESTORS LP | SC 13G | 13,400,000 | 6.7% | Apr 24, 2026 | SEC filing |
| Apr 30, 2026 | Deep Track Capital, LP | SC 13G | 19,417,221 | 10.0% | Apr 23, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Jan 30, 2026 | The Vanguard Group | SC 13G/A | 9,491,159 | 9.1% | Dec 31, 2025 | SEC filing |
| Jul 16, 2025 | BlackRock, Inc. | SC 13G/A | 6,133,427 | 7.6% | Jun 30, 2025 | SEC filing |
| May 15, 2025 | Ameriprise Financial, Inc. | SC 13G/A | 1,443,932 | 1.9% | Mar 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 17 Lobbying Disclosure Act filings named this company as client, 2020–2022; most common issues: Health Issues (14), Manufacturing (6), Budget/Appropriations (6).
Federal contracts: $1.6M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $2.9M |
| FY2022 | $-332.0K |
| FY2023 | $0 |
| FY2024 | $-956.0K |
| FY2025 | $0 |
| FY2026 | $0 |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| HHSO100201600008C | Department of Health and Human Services | $29.9M | Jul 27, 2016 |
| HHSN272201400040C | Department of Health and Human Services | $14.7M | Jul 23, 2014 |
| HHSO10033001T | Department of Health and Human Services | $979.5K | Sep 17, 2013 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Insiders
· Insider Cluster Buying — Last 90 days: 3 or more different insiders bought on the open market
· CEO & CFO Buying — Last 90 days: top executives (CEO/CFO) bought on the open market
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
Financial Screens
· Net-Net (NCAV) — Market cap below net current asset value
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Net-Net (NCAV) — NCAV: $223.2M · Market cap: $188.5M · NCAV / market cap: 1.18
· Insider Cluster Buying — Insiders buying: 4 · Buy txns: 4 · Buy value: $96.4K · Latest buy: Nov 18, 2026
· CEO & CFO Buying — Buy txns: 4 · Buy value: $96.4K · Insiders buying: 4 · Latest buy: Nov 18, 2026
· Insider Net Buying — Buy txns: 4 · Sell txns: 0 · Buy value: $96.4K · Latest buy: Nov 18, 2026
· Distress Risk (Altman Z″) — Z″-Score: 0.63 · Working capital / assets: 0.94 · Retained earnings / assets: -2.32 · EBIT / assets: -0.34 · Equity / liabilities: 4.09
· Excess Accruals (Sloan) — Accruals ratio: 40.0% · Net income: $-88.1M · Operating cash flow: $-67.5M · Investing cash flow: $-132.5M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 3 of the last 20 quarterly lists; latest 2026 Q1, ranked #20 of 50.
Also held by the tracked funds that hold ALT — ranked by lift, the co-holding pattern described in Methodology: Oruka Therapeutics, Inc. (ORKA) · Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT).
7 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 12, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 29, 2026 | 2.03 Creation of a Direct Financial Obligation | SEC filing |
| Oct 27, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Oruka Therapeutics, Inc. (ORKA) · Track Record: how the signals scored · Practice timing on ALT
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.